News headlines about Affimed N.V. (NASDAQ:AFMD) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Affimed N.V. earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.4243644883199 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
AFMD has been the topic of several recent research reports. SunTrust Banks, Inc. initiated coverage on shares of Affimed N.V. in a report on Thursday, July 13th. They set a “buy” rating and a $7.00 target price on the stock. ValuEngine upgraded shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $2.50 price target on shares of Affimed N.V. in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $5.38.
Affimed N.V. (NASDAQ:AFMD) traded down 1.250% during mid-day trading on Friday, hitting $1.975. 245,562 shares of the stock were exchanged. The firm’s market cap is $86.78 million. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $2.95. The company has a 50 day moving average of $2.16 and a 200 day moving average of $2.19.
Affimed N.V. (NASDAQ:AFMD) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $1.31 million. During the same quarter last year, the firm earned ($0.24) EPS. The business’s revenue was down 75.4% on a year-over-year basis. On average, equities analysts anticipate that Affimed N.V. will post ($0.83) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Affimed N.V. (NASDAQ:AFMD) Earning Somewhat Favorable Media Coverage, Accern Reports” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/affimed-n-v-afmd-earning-somewhat-positive-press-coverage-report-shows.html.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.